Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A quality control portal for sequencing data deposited at the European genome-phenome archive

  • Fernández-Orth, Dietmar
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Moldes, Mauricio
  • Jene, Aina
  • Ferri, Marta
  • Vasallo, Claudia
  • Fromont, Lauren A.
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
Since its launch in 2008, the European Genome-Phenome Archive (EGA) has been leading the archiving and distribution of human identifiable genomic data. In this regard, one of the community concerns is the potential usability of the stored data, as of now, data submitters are not mandated to perform any quality control (QC) before uploading their data and associated metadata information. Here, we present a new File QC Portal developed at EGA, along with QC reports performed and created for 1 694 442 files [Fastq, sequence alignment map (SAM)/binary alignment map (BAM)/CRAM and variant call format (VCF)] submitted at EGA. QC reports allow anonymous EGA users to view summary-level information regarding the files within a specific dataset, such as quality of reads, alignment quality, number and type of variants and other features. Researchers benefit from being able to assess the quality of data prior to the data access decision and thereby, increasing the reusability of data (https://ega-archive.org/blog/data-upcycling-powered-by-ega/)., Funding: the File QC feature project has received funding from Horizon 2020 ELIXIR-CONVERGE project (grant agreement No 871075), the ELIXIR-FHD-IS and La Caixa Foundation (LCF/PR/CE20/50740008)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A research data management (RDM) community for ELIXIR

  • D'Anna, Flora
  • D'Altri, Teresa, 1984-
  • Andrabi, Munazah
Research data management (RDM) is central to the implementation of the FAIR (Findable Accessible, Interoperable, Reusable) and Open Science principles. Recognising the importance of RDM, ELIXIR Platforms and Nodes have invested in RDM and launched various projects and initiatives to ensure good data management practices for scientific excellence. These projects have resulted in a rich set of tools and resources highly valuable for FAIR data management. However, these resources remain scattered across projects and ELIXIR structures, making their dissemination and application challenging. Therefore, it becomes imminent to coordinate these efforts for sustainable and harmonised RDM practices with dedicated forums for RDM professionals to exchange knowledge and share resources. The proposed ELIXIR RDM Community will bring together RDM experts to develop ELIXIR's vision and coordinate its activities, taking advantage of the available assets. It aims to coordinate RDM best practices and illustrate how to use the existing ELIXIR RDM services. The Community will be built around three integral pillars, namely, a network of RDM professionals, RDM knowledge management and RDM training expertise and resources. It will also engage with external stakeholders to leverage benefits and provide a forum to RDM professionals for regular knowledge exchange, capacity building and development of harmonised RDM practices, keeping in line with the overall scope of the RDM Community. In the short term, the Community aims to build upon the existing resources and ensure that the content of these remain up to date and fit for purpose. In the long run, the Community will aim to strengthen the skills and knowledge of its RDM professionals to support the emerging needs of the scientific community. The Community will also devise an effective strategy to engage with other ELIXIR structures and international stakeholders to influence and align with developments and solutions in the RDM field., ELIXIR-CONVERGE: European Union’s Horizon 2020 programme under grant agreement No 871075. FAIRplus: European Union’s Horizon 2020 programme under grant agreement No 802750.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

The integrated genomic surveillance system of Andalusia (SIEGA) provides a One Health regional resource connected with the clinic

  • Casimiro Soriguer, Carlos S.
  • Perez Florido, Javier
  • Robles, Enrique
  • Lara, María
  • Aguado, Andrea
  • Rodríguez Iglesias, Manuel Antonio
  • Lepe, Jose A.
  • García, Federico
  • Pérez Alegre, Mónica
  • Andújar, Eloísa
  • Jiménez, Victoria E.
  • Camino, Lola P.
  • Loruso, Nicola
  • Ameyugo, Ulises
  • Vazquez, Isabel María
  • Lozano, Carlota M.
  • Chaves, J. Alberto
  • Dopazo, Joaquín
The One Health approach, recognizing the interconnectedness of human, animal, and environmental health, has gained significance amid emerging zoonotic diseases and antibiotic resistance concerns. This paper aims to demonstrate the utility of a collaborative tool, the SIEGA, for monitoring infectious diseases across domains, fostering a comprehensive understanding of disease dynamics and risk factors, highlighting the pivotal role of One Health surveillance systems. Raw whole-genome sequencing is processed through different species-specific open software that additionally reports the presence of genes associated to anti-microbial resistances and virulence. The SIEGA application is a Laboratory Information Management System, that allows customizing reports, detect transmission chains, and promptly alert on alarming genetic similarities. The SIEGA initiative has successfully accumulated a comprehensive collection of more than 1900 bacterial genomes, including Salmonella enterica, Listeria monocytogenes, Campylobacter jejuni, Escherichia coli, Yersinia enterocolitica and Legionella pneumophila, showcasing its potential in monitoring pathogen transmission, resistance patterns, and virulence factors. SIEGA enables customizable reports and prompt detection of transmission chains, highlighting its contribution to enhancing vigilance and response capabilities. Here we show the potential of genomics in One Health surveillance when supported by an appropriate bioinformatic tool. By facilitating precise disease control strategies and antimicrobial resistance management, SIEGA enhances global health security and reduces the burden of infectious diseases. The integration of health data from humans, animals, and the environment, coupled with advanced genomics, underscores the importance of a holistic One Health approach in mitigating health threats.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival

  • Loucera, Carlos
  • Pérez-Florido, Javier
  • Casimiro-Soriguer, Carlos S.
  • Ortuño, Francisco M.
  • Carmona, Rosario
  • Bostelmann, Gerrit
  • Martínez-González, Luis Javier
  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • Rodríguez-Baño, Jesús
  • Romero-Gómez, Manuel
  • Lorusso, Nicola
  • García-León, Francisco Javier
  • Navarro-Marí, José María
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Salazar, Adolfo de
  • Viñuela, Laura
  • The Andalusian COVID-19 Sequencing Initiative
  • Lepe, José A.
  • García, Federico
  • Dopazo, Joaquín
Objectives: More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain. Methods: A total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis. Results: A significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins. Conclusions: This study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival., This work was supported by Spanish Ministry of Science and Innovation (grant PID2020- 117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Familias, Junta de Andalucía (grants COVID-0012-2020 and PS-2020-342) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350), co-funded by the European Social Fund (FSE) 2014-2020. ELIXIR-CONVERGE—H2020 (871075)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

  • Casimiro-Soriguer, Carlos S.
  • Pérez-Florido, Javier
  • Lara, María
  • Camacho‐Martínez, Pedro
  • Merino Díaz, Laura
  • Pupo Ledo, María Inmaculada
  • Salazar, Adolfo de
  • Fuentes, Ana
  • Viñuela, Laura
  • Chueca, Natalia
  • Martínez-Martínez, Luis
  • Lorusso, Nicola
  • Andalusian Genomic Surveillance Network
  • Lepe, José A.
  • Dopazo, Joaquín
  • García, Federico
Until the May 2022 Monkeypox outbreak, which spread rapidly to many non-endemic countries, the virus was considered a viral zoonosis limited to some African countries. The Andalusian circuit of genomic surveillance was rapidly applied to characterize the Monkeypox outbreak in the South of Spain. Whole genome sequencing was used to obtain the genomic profiles of samples collected across the south of Spain, representative of all the provinces of Andalusia. Phylogenetic analysis was used to study the relationship of the isolates and the available sequences of the 2022 outbreak. Whole genome sequencing of a total of 160 monkeypox viruses from the different provinces that reported cases were obtained. Interestingly, we report the sequences of monkeypox viruses obtained from two patients who died. While one of the isolates bore no noteworthy mutations that explain a potential heightened virulence, in another patient the second consecutive genome sequence, performed after the administration of tecovirimat, uncovered a mutation within the A0A7H0DN30 gene, known to be a prime target for tecovirimat in its Vaccinia counterpart. In general, a low number of mutations were observed in the sequences reported, which were very similar to the reference of the 2022 outbreak (OX044336), as expected from a DNA virus. The samples likely correspond to several introductions of the circulating monkeypox viruses from the last outbreak. The virus sequenced from one of the two patients that died presented a mutation in a gene that bears potential connections to drug resistance. This mutation was absent in the initial sequencing prior to treatment, This work was supported by Spanish Ministry of Science and Innovation (grants PID2020- 117979RB-I00 and FJC2021-046546-I), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), it has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020), and by grant ELIXIR-CONVERGE - Connect and align ELIXIR Nodes to deliver sustainable FAIR lifescience data management services (AMD-871075-16), funded by EU – H2020., No
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Extensible benchmarking of methods that identify and quantify polyadenylation sites from RNA-seq data

  • Bryce-Smith, Sam
  • Burri, Dominik
  • Gazzara, Matthew R.
  • Herrmann, Christina J.
  • Danecka, Weronika
  • Feranandez, José M.
  • Ferret, Meritxell
  • Gonzalez Uriarte, Asier
The tremendous rate with which data is generated and analysis methods emerge makes it increasingly difficult to keep track of their domain of applicability, assumptions, limitations, and consequently, of the efficacy and precision with which they solve specific tasks. Therefore, there is an increasing need for benchmarks, and for the provision of infrastructure for continuous method evaluation. APAeval is an international community effort, organized by the RNA Society in 2021, to benchmark tools for the identification and quantification of the usage of alternative polyadenylation (APA) sites from short-read, bulk RNA-sequencing (RNA-seq) data. Here, we reviewed 17 tools and benchmarked eight on their ability to perform APA identification and quantification, using a comprehensive set of RNA-seq experiments comprising real, synthetic, and matched 3′-end sequencing data. To support continuous benchmarking, we have incorporated the results into the OpenEBench online platform, which allows for continuous extension of the set of methods, metrics, and challenges. We envisage that our analyses will assist researchers in selecting the appropriate tools for their studies, while the containers and reproducible workflows could easily be deployed and extended to evaluate new methods or data sets., We thank the RNA Society for making the hackathon possible and bringing together people from various disciplines. We thank the OpenEBench platform (https://openebench.bsc.es/) for hosting the APAeval benchmark. We thank OEB members Anna Redondo, Laura Portell, Laura Rodriguez-Navas, and Salvador Capella for help and contributions. We thank Seqera Labs (https://seqera.io/) for kindly hosting a workshop regarding the use of Nextflow and Nextflow Tower during the RNA Society 2021 meeting, and Amazon Web Services for providing us with credits for the use of their cloud platform. We are grateful to host the source code on the iRNA COSI (https://irnacosi.org/) GitHub account. S.B.-S. was supported by a UK Motor Neurone Disease Association and Masonic Charitable Foundation PhD Studentship (893-792). C.M.F. was partially supported by a postdoctoral fellowship from the American Cancer Society (PF-19-157-01-RMC). M.R.G. was supported by the Blavatnik Family Fellowship in Biomedical Research and by NHLBI of the National Institutes of Health (NIH) under award number F31 HL162546. A.G.-U. was supported by the The Emerging Human Brain Cluster (Clúster Emergent del Cervell Humà – CECH) project, number 001-P-001682, 50% cofunded by the European Regional Development Fund of the European Union (Programa Operatiu FEDER Catalunya 2014–2020), with the support of the Catalan Government. Y.K.W. was supported by the Singapore International Graduate Award. OpenEBench is partly funded by the Horizon 2020 ELIXIR-CONVERGE programme, grant agreement number 871075. The work of Y.B. was supported by R01 GM128096, R01 GM147739, and R01 LM013437. D.B. and C.J.H. were partially supported by the Swiss National Science Foundation grant number 310030_189063 to M.Z., Peer Reviewed, "Article signat per 26 autors/es: Sam Bryce-Smith, Dominik Burri, Matthew R. Gazzara, Christina J. Herrmann, Weronika Danecka, Christina M. Fitzsimmons, Yuk Kei Wan, Farica Zhuang, Mervin M. Fansler, José M. Fernández, Meritxell Ferret, Asier Gonzalez-Uriarte, Samuel Haynes, Chelsea Herdman, Alexander Kanitz, Maria Katsantoni, Federico Marini, Euan McDonnel, Ben Nicolet, Chi-Lam Poon, Gregor Rot, Leonard Schärfen, Pin-Jou Wu, Yoseop Yoon, Yoseph Barash and Mihaela Zavolan"
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Making Canonical Workflow Building Blocks Interoperable across Workflow Languages

  • Soiland Reyes, Stian
  • Bayarri, Genís
  • Andrio, Pau
  • Long, Robin
  • Lowe, Douglas
  • Niewielska, Ania
  • Hospital, Adam
  • Groth, Paul
We introduce the concept of Canonical Workflow Building Blocks (CWBB), a methodology of describing and wrapping computational tools, in order for them to be utilised in a reproducible manner from multiple workflow languages and execution platforms. The concept is implemented and demonstrated with the BioExcel Building Blocks library (BioBB), a collection of tool wrappers in the field of computational biomolecular simulation. Interoperability across different workflow languages is showcased through a protein Molecular Dynamics setup transversal workflow, built using this library and run with 5 different Workflow Manager Systems (WfMS). We argue such practice is a necessary requirement for FAIR Computational Workflows and an element of Canonical Workflow Frameworks for Research (CWFR) in order to improve widespread adoption and reuse of computational methods across workflow language barriers., This work has been done as part of the BioExcel CoE (https://www.bioexcel.eu/), a project funded by the European Union contracts H2020-INFRAEDI-02-2018 823830, and H2020-EINFRA-2015-1 675728. Additional work is funded through EOSC-Life (https://www.eosc-life.eu/) contract H2020-INFRAEOSC-2018-2 824087, and ELIXIR-CONVERGE (https://elixir-europe.org/) contract H2020-INFRADEV-2019-2 871075. The authors would also like to acknowledge contributions from Cibin Sadasivan Baby, Finn Bacall, Rosa M. Badia, Sarah Butcher, Gerard Capes, Michael R. Crusoe, Alberto Eusebi, Carole Goble, Josep Lluís Gelpí, Modesto Orozco, Geoff Williams, and Felix Amaladoss., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Extensible benchmarking of methods that identify and quantify polyadenylation sites from RNA-seq data

  • Bryce-Smith, Sam
  • Burri, Dominik
  • Gazzara, Matthew R.
  • Herrmann, Christina J.
  • Danecka, Weronika
  • Feranandez, José M.
  • Ferret, Meritxell
  • Gonzalez Uriarte, Asier
The tremendous rate with which data is generated and analysis methods emerge makes it increasingly difficult to keep track of their domain of applicability, assumptions, limitations, and consequently, of the efficacy and precision with which they solve specific tasks. Therefore, there is an increasing need for benchmarks, and for the provision of infrastructure for continuous method evaluation. APAeval is an international community effort, organized by the RNA Society in 2021, to benchmark tools for the identification and quantification of the usage of alternative polyadenylation (APA) sites from short-read, bulk RNA-sequencing (RNA-seq) data. Here, we reviewed 17 tools and benchmarked eight on their ability to perform APA identification and quantification, using a comprehensive set of RNA-seq experiments comprising real, synthetic, and matched 3′-end sequencing data. To support continuous benchmarking, we have incorporated the results into the OpenEBench online platform, which allows for continuous extension of the set of methods, metrics, and challenges. We envisage that our analyses will assist researchers in selecting the appropriate tools for their studies, while the containers and reproducible workflows could easily be deployed and extended to evaluate new methods or data sets., We thank the RNA Society for making the hackathon possible and bringing together people from various disciplines. We thank the OpenEBench platform (https://openebench.bsc.es/) for hosting the APAeval benchmark. We thank OEB members Anna Redondo, Laura Portell, Laura Rodriguez-Navas, and Salvador Capella for help and contributions. We thank Seqera Labs (https://seqera.io/) for kindly hosting a workshop regarding the use of Nextflow and Nextflow Tower during the RNA Society 2021 meeting, and Amazon Web Services for providing us with credits for the use of their cloud platform. We are grateful to host the source code on the iRNA COSI (https://irnacosi.org/) GitHub account. S.B.-S. was supported by a UK Motor Neurone Disease Association and Masonic Charitable Foundation PhD Studentship (893-792). C.M.F. was partially supported by a postdoctoral fellowship from the American Cancer Society (PF-19-157-01-RMC). M.R.G. was supported by the Blavatnik Family Fellowship in Biomedical Research and by NHLBI of the National Institutes of Health (NIH) under award number F31 HL162546. A.G.-U. was supported by the The Emerging Human Brain Cluster (Clúster Emergent del Cervell Humà – CECH) project, number 001-P-001682, 50% cofunded by the European Regional Development Fund of the European Union (Programa Operatiu FEDER Catalunya 2014–2020), with the support of the Catalan Government. Y.K.W. was supported by the Singapore International Graduate Award. OpenEBench is partly funded by the Horizon 2020 ELIXIR-CONVERGE programme, grant agreement number 871075. The work of Y.B. was supported by R01 GM128096, R01 GM147739, and R01 LM013437. D.B. and C.J.H. were partially supported by the Swiss National Science Foundation grant number 310030_189063 to M.Z., Peer Reviewed, "Article signat per 26 autors/es: Sam Bryce-Smith, Dominik Burri, Matthew R. Gazzara, Christina J. Herrmann, Weronika Danecka, Christina M. Fitzsimmons, Yuk Kei Wan, Farica Zhuang, Mervin M. Fansler, José M. Fernández, Meritxell Ferret, Asier Gonzalez-Uriarte, Samuel Haynes, Chelsea Herdman, Alexander Kanitz, Maria Katsantoni, Federico Marini, Euan McDonnel, Ben Nicolet, Chi-Lam Poon, Gregor Rot, Leonard Schärfen, Pin-Jou Wu, Yoseop Yoon, Yoseph Barash and Mihaela Zavolan", Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A quality control portal for sequencing data deposited at the European genome-phenome archive

  • Fernández-Orth, Dietmar
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Moldes, Mauricio
  • Jene, Aina
  • Ferri, Marta
  • Vasallo, Claudia
  • Fromont, Lauren A.
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
Since its launch in 2008, the European Genome-Phenome Archive (EGA) has been leading the archiving and distribution of human identifiable genomic data. In this regard, one of the community concerns is the potential usability of the stored data, as of now, data submitters are not mandated to perform any quality control (QC) before uploading their data and associated metadata information. Here, we present a new File QC Portal developed at EGA, along with QC reports performed and created for 1 694 442 files [Fastq, sequence alignment map (SAM)/binary alignment map (BAM)/CRAM and variant call format (VCF)] submitted at EGA. QC reports allow anonymous EGA users to view summary-level information regarding the files within a specific dataset, such as quality of reads, alignment quality, number and type of variants and other features. Researchers benefit from being able to assess the quality of data prior to the data access decision and thereby, increasing the reusability of data (https://ega-archive.org/blog/data-upcycling-powered-by-ega/)., Funding: the File QC feature project has received funding from Horizon 2020 ELIXIR-CONVERGE project (grant agreement No 871075), the ELIXIR-FHD-IS and La Caixa Foundation (LCF/PR/CE20/50740008)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Making Canonical Workflow Building Blocks Interoperable across Workflow Languages

  • Soiland Reyes, Stian
  • Bayarri, Genís
  • Andrio, Pau
  • Long, Robin
  • Lowe, Douglas
  • Niewielska, Ania
  • Hospital, Adam
  • Groth, Paul
We introduce the concept of Canonical Workflow Building Blocks (CWBB), a methodology of describing and wrapping computational tools, in order for them to be utilised in a reproducible manner from multiple workflow languages and execution platforms. The concept is implemented and demonstrated with the BioExcel Building Blocks library (BioBB), a collection of tool wrappers in the field of computational biomolecular simulation. Interoperability across different workflow languages is showcased through a protein Molecular Dynamics setup transversal workflow, built using this library and run with 5 different Workflow Manager Systems (WfMS). We argue such practice is a necessary requirement for FAIR Computational Workflows and an element of Canonical Workflow Frameworks for Research (CWFR) in order to improve widespread adoption and reuse of computational methods across workflow language barriers., This work has been done as part of the BioExcel CoE (https://www.bioexcel.eu/), a project funded by the European Union contracts H2020-INFRAEDI-02-2018 823830, and H2020-EINFRA-2015-1 675728. Additional work is funded through EOSC-Life (https://www.eosc-life.eu/) contract H2020-INFRAEOSC-2018-2 824087, and ELIXIR-CONVERGE (https://elixir-europe.org/) contract H2020-INFRADEV-2019-2 871075. The authors would also like to acknowledge contributions from Cibin Sadasivan Baby, Finn Bacall, Rosa M. Badia, Sarah Butcher, Gerard Capes, Michael R. Crusoe, Alberto Eusebi, Carole Goble, Josep Lluís Gelpí, Modesto Orozco, Geoff Williams, and Felix Amaladoss., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A research data management (RDM) community for ELIXIR

  • D'Anna, Flora
  • D'Altri, Teresa, 1984-
  • Andrabi, Munazah
Research data management (RDM) is central to the implementation of the FAIR (Findable Accessible, Interoperable, Reusable) and Open Science principles. Recognising the importance of RDM, ELIXIR Platforms and Nodes have invested in RDM and launched various projects and initiatives to ensure good data management practices for scientific excellence. These projects have resulted in a rich set of tools and resources highly valuable for FAIR data management. However, these resources remain scattered across projects and ELIXIR structures, making their dissemination and application challenging. Therefore, it becomes imminent to coordinate these efforts for sustainable and harmonised RDM practices with dedicated forums for RDM professionals to exchange knowledge and share resources. The proposed ELIXIR RDM Community will bring together RDM experts to develop ELIXIR's vision and coordinate its activities, taking advantage of the available assets. It aims to coordinate RDM best practices and illustrate how to use the existing ELIXIR RDM services. The Community will be built around three integral pillars, namely, a network of RDM professionals, RDM knowledge management and RDM training expertise and resources. It will also engage with external stakeholders to leverage benefits and provide a forum to RDM professionals for regular knowledge exchange, capacity building and development of harmonised RDM practices, keeping in line with the overall scope of the RDM Community. In the short term, the Community aims to build upon the existing resources and ensure that the content of these remain up to date and fit for purpose. In the long run, the Community will aim to strengthen the skills and knowledge of its RDM professionals to support the emerging needs of the scientific community. The Community will also devise an effective strategy to engage with other ELIXIR structures and international stakeholders to influence and align with developments and solutions in the RDM field., ELIXIR-CONVERGE: European Union’s Horizon 2020 programme under grant agreement No 871075. FAIRplus: European Union’s Horizon 2020 programme under grant agreement No 802750.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].